Visit Contract Pharma
at Stand No. 1G97

Novasep to Expand Cryogenic Production Capacity

10.24.17

Will invest €4 million to expand cGMP capacity for clinical and commercial supply of APIs at its Chasse-sur-Rhône facility

Novasep is investing €4 million to expand cGMP capacity for clinical and commercial supply of APIs at its Chasse-sur-Rhône (FR) facility.

The investment includes the installation of a new cGMP cryogenic production line, capable of operating at temperatures as low as -80°C. It is equipped with a 4m3 Hastelloy reactor, filter drier and clean room.

The investment also includes an expansion of the cGMP pilot-plant capabilities with the addition of a new stream comprising a 400L Hastelloy reactor, filter drier and clean room. This will add flexible small-scale manufacturing capacity and enhance the site's capability to handle both clinical development needs and low volume APIs.

The expansion will bring Novasep's total low temperature capacity to more than 35m3 and is expected to be operational in early 2018.  

"By increasing cryogenics capacity at the current Chasse-sur-Rhône facility, we strengthen Novasep's small and large-scale volume offering for low temperature manufacturing." Jean-Pierre Pilleux, General Manager of the Chasse-sur-Rhône site said, "It will give us more flexibility and allow us to address the increasing market demand for these types of capabilities."